FDA Imposes Full Clinical Hold on Lead Drug ARD-101, Halting Phase 3 Trials

summarizeSummary

Aardvark Therapeutics announced that the FDA has placed a full clinical hold on its lead investigational drug, ARD-101, halting all ongoing clinical studies, including Phase 3 trials for Prader-Willi Syndrome.

check_boxKey Events

• FDA Imposes Full Clinical Hold

  The U.S. Food and Drug Administration (FDA) has placed a full clinical hold on Aardvark Therapeutics' investigational new drug application (IND) for ARD-101.

• Phase 3 Trials Halted

  The clinical hold applies to all ongoing studies under the IND, including the Phase 3 HERO trial and the open-label extension (OLE) trial for Prader-Willi Syndrome.

• Follows Voluntary Pause

  This regulatory action follows the company's previously announced voluntary pause in its Phase 3 trials due to safety observations.

• Company to Unblind Data

  Aardvark Therapeutics plans to unblind clinical data from both trials to assess efficacy and safety, informing next steps for the ARD-101 program.

auto_awesomeAnalysis

The FDA's decision to place a full clinical hold on ARD-101 is a critical setback for Aardvark Therapeutics, as it directly impacts their lead drug candidate in Phase 3 trials for Prader-Willi Syndrome. This escalates the previously announced voluntary trial pauses to a regulatory mandate, casting significant doubt on the program's future and the company's primary value driver. While the company plans to unblind data and engage with the FDA, the hold represents a major blow to investor confidence and the company's ability to bring ARD-101 to market.